MIRA Pharmaceuticals (MIRA) Competitors

$0.99 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$1.00 +0.01 (+0.71%)

As of 05/22/2026 06:55 PM Eastern

MIRA vs. ADAG, HRTX, IMUX, PLX, and ABOS

Should you buy MIRA Pharmaceuticals stock or one of its competitors? MarketBeat compares MIRA Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MIRA Pharmaceuticals include Adagene (ADAG), Heron Therapeutics (HRTX), Immunic (IMUX), Protalix BioTherapeutics (PLX), and Acumen Pharmaceuticals (ABOS). These companies are all part of the "pharmaceutical products" industry.

How does MIRA Pharmaceuticals compare to Adagene?

MIRA Pharmaceuticals (NASDAQ:MIRA) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

MIRA Pharmaceuticals has higher earnings, but lower revenue than Adagene.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A
Adagene	$7.67M	23.17	-$17.61M	N/A	N/A

Adagene has a consensus target price of $8.00, suggesting a potential upside of 113.33%. Given Adagene's stronger consensus rating and higher probable upside, analysts clearly believe Adagene is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

Adagene's return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%
Adagene	N/A	N/A	N/A

MIRA Pharmaceuticals has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market. Comparatively, Adagene has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market.

35.2% of MIRA Pharmaceuticals shares are held by institutional investors. Comparatively, 9.5% of Adagene shares are held by institutional investors. 6.7% of MIRA Pharmaceuticals shares are held by insiders. Comparatively, 21.2% of Adagene shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Adagene had 1 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 1 mentions for Adagene and 0 mentions for MIRA Pharmaceuticals. Adagene's average media sentiment score of 0.15 beat MIRA Pharmaceuticals' score of 0.00 indicating that Adagene is being referred to more favorably in the news media.

Company	Overall Sentiment
MIRA Pharmaceuticals	Neutral
Adagene	Neutral

Summary

Adagene beats MIRA Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to Heron Therapeutics?

Heron Therapeutics (NASDAQ:HRTX) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

MIRA Pharmaceuticals has a net margin of 0.00% compared to Heron Therapeutics' net margin of -20.53%. MIRA Pharmaceuticals' return on equity of -140.82% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%

In the previous week, Heron Therapeutics had 1 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 1 mentions for Heron Therapeutics and 0 mentions for MIRA Pharmaceuticals. Heron Therapeutics' average media sentiment score of 0.87 beat MIRA Pharmaceuticals' score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Heron Therapeutics	Positive
MIRA Pharmaceuticals	Neutral

80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. 5.9% of Heron Therapeutics shares are owned by insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Heron Therapeutics currently has a consensus price target of $4.50, indicating a potential upside of 423.99%. Given Heron Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Heron Therapeutics is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Heron Therapeutics has a beta of 1.7, meaning that its share price is 70% more volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market.

MIRA Pharmaceuticals has lower revenue, but higher earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$154.90M	1.05	-$20.19M	-$0.18	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A

Summary

Heron Therapeutics beats MIRA Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to Immunic?

Immunic (NASDAQ:IMUX) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

51.8% of Immunic shares are held by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 14.0% of Immunic shares are held by insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Immunic has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market.

Immunic is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A

MIRA Pharmaceuticals' return on equity of -140.82% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-220.75%	-132.04%
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%

In the previous week, Immunic had 13 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 13 mentions for Immunic and 0 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 0.00 beat Immunic's score of -0.52 indicating that MIRA Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Immunic	Negative
MIRA Pharmaceuticals	Neutral

Immunic currently has a consensus target price of $47.57, suggesting a potential upside of 264.53%. Given Immunic's stronger consensus rating and higher possible upside, research analysts clearly believe Immunic is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Immunic beats MIRA Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to Protalix BioTherapeutics?

MIRA Pharmaceuticals (NASDAQ:MIRA) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

Protalix BioTherapeutics has higher revenue and earnings than MIRA Pharmaceuticals. MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A
Protalix BioTherapeutics	$76.38M	2.22	$8.31M	$0.18	11.67

MIRA Pharmaceuticals has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

MIRA Pharmaceuticals has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market. Comparatively, Protalix BioTherapeutics has a beta of -0.01, meaning that its share price is 101% less volatile than the broader market.

35.2% of MIRA Pharmaceuticals shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 6.7% of MIRA Pharmaceuticals shares are held by insiders. Comparatively, 6.5% of Protalix BioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Protalix BioTherapeutics had 5 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 5 mentions for Protalix BioTherapeutics and 0 mentions for MIRA Pharmaceuticals. Protalix BioTherapeutics' average media sentiment score of 0.70 beat MIRA Pharmaceuticals' score of 0.00 indicating that Protalix BioTherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
MIRA Pharmaceuticals	Neutral
Protalix BioTherapeutics	Positive

Protalix BioTherapeutics has a consensus target price of $12.00, indicating a potential upside of 471.43%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Protalix BioTherapeutics is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Protalix BioTherapeutics beats MIRA Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to Acumen Pharmaceuticals?

MIRA Pharmaceuticals (NASDAQ:MIRA) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

In the previous week, Acumen Pharmaceuticals had 2 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 2 mentions for Acumen Pharmaceuticals and 0 mentions for MIRA Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 0.25 beat MIRA Pharmaceuticals' score of 0.00 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
MIRA Pharmaceuticals	Neutral
Acumen Pharmaceuticals	Neutral

35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 6.7% of MIRA Pharmaceuticals shares are owned by insiders. Comparatively, 9.3% of Acumen Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A

Acumen Pharmaceuticals has a consensus target price of $6.67, indicating a potential upside of 165.60%. Given Acumen Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

MIRA Pharmaceuticals has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

Acumen Pharmaceuticals' return on equity of -123.07% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%

Summary

Acumen Pharmaceuticals beats MIRA Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

Get MIRA Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MIRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MIRA vs. The Competition

Export

Metric	MIRA Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$41.69M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-0.76	18.74	20.99	25.66
Price / Sales	N/A	323.98	560.30	86.31
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	4.51	7.09	10.41	7.14
Net Income	-$10.44M	$24.45M	$3.57B	$335.98M
7 Day Performance	4.42%	6.38%	6.41%	4.15%
1 Month Performance	-5.52%	2.43%	3.55%	2.54%
1 Year Performance	-18.69%	62.98%	34.12%	35.06%

MIRA Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MIRA MIRA Pharmaceuticals	0.4574 of 5 stars	$0.99 flat	N/A	-18.7%	$41.69M	N/A	N/A	2
ADAG Adagene	2.6944 of 5 stars	$3.43 +1.2%	$8.00 +133.2%	+106.0%	$162.31M	$7.67M	N/A	260	Gap Down
HRTX Heron Therapeutics	2.463 of 5 stars	$0.85 -0.6%	$4.50 +426.9%	-53.6%	$161.64M	$150.71M	N/A	300	Gap Up
IMUX Immunic	3.7975 of 5 stars	$11.70 +0.3%	$50.86 +334.7%	+42.2%	$159.37M	N/A	N/A	70	Gap Down
PLX Protalix BioTherapeutics	3.3008 of 5 stars	$1.98 +3.4%	$12.00 +507.6%	+29.6%	$159.13M	$76.38M	N/A	200	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MIRA) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MIRA Pharmaceuticals (MIRA) Competitors

MIRA vs. ADAG, HRTX, IMUX, PLX, and ABOS

How does MIRA Pharmaceuticals compare to Adagene?

Summary

How does MIRA Pharmaceuticals compare to Heron Therapeutics?

Summary

How does MIRA Pharmaceuticals compare to Immunic?

Summary

How does MIRA Pharmaceuticals compare to Protalix BioTherapeutics?

Summary

How does MIRA Pharmaceuticals compare to Acumen Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRA vs. The Competition

MIRA Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MIRA Pharmaceuticals (MIRA) Competitors

MIRA vs. ADAG, HRTX, IMUX, PLX, and ABOS

How does MIRA Pharmaceuticals compare to Adagene?

Which has higher valuation and earnings, MIRA or ADAG?

Do analysts prefer MIRA or ADAG?

Is MIRA or ADAG more profitable?

Which has more risk and volatility, MIRA or ADAG?

Do insiders and institutionals hold more shares of MIRA or ADAG?

Does the media refer more to MIRA or ADAG?

Summary

How does MIRA Pharmaceuticals compare to Heron Therapeutics?

Is HRTX or MIRA more profitable?

Does the media favor HRTX or MIRA?

Do institutionals & insiders believe in HRTX or MIRA?

Do analysts prefer HRTX or MIRA?

Which has more volatility and risk, HRTX or MIRA?

Which has better earnings & valuation, HRTX or MIRA?

Summary

How does MIRA Pharmaceuticals compare to Immunic?

Do insiders and institutionals have more ownership in IMUX or MIRA?

Which has more volatility and risk, IMUX or MIRA?

Which has better earnings and valuation, IMUX or MIRA?

Is IMUX or MIRA more profitable?

Does the media favor IMUX or MIRA?

Do analysts recommend IMUX or MIRA?

Summary

How does MIRA Pharmaceuticals compare to Protalix BioTherapeutics?

Which has higher earnings and valuation, MIRA or PLX?

Is MIRA or PLX more profitable?

Which has more risk and volatility, MIRA or PLX?

Do institutionals & insiders have more ownership in MIRA or PLX?

Does the media refer more to MIRA or PLX?

Do analysts rate MIRA or PLX?

Summary

How does MIRA Pharmaceuticals compare to Acumen Pharmaceuticals?

Does the media refer more to MIRA or ABOS?

Do insiders and institutionals believe in MIRA or ABOS?

Which has stronger earnings and valuation, MIRA or ABOS?

Do analysts prefer MIRA or ABOS?

Which has more risk and volatility, MIRA or ABOS?

Is MIRA or ABOS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRA vs. The Competition

MIRA Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools